Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + R2 in R/R CD20+ B-cell Lymphoma
NCT05014100Phase 2Unknown
- Sponsor
- Puyang Oilfield General Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in B cell lymphoma, sponsored by Puyang Oilfield General Hospital. Primary endpoint: Complete Response Rate at 1 year. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05014100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014100.